Improving Adherence with Patient-Centric Formulations
The term “patient centered,” “patient centric,” or “patient centricity” has increasingly grown in use in the scientific community in a wide variety of contexts. Generally, patient centric medicines are recognized as an essential contributor to healthy aging and the overall patient’s quality of life and life expectancy. However, developing patient centric medicines can pose an alternative approach, away from the traditional drug development, scientific process.
Arguably the most significant compliance challenge in older people is polypharmacy, whereas for children the largest barrier is taste. Pharmaceutical technology has progressed rapidly and technologies including FDCs, multi-particulates and orodispersible dosage forms provide unprecedented opportunities to develop novel and appropriate formulations for both old and new drugs. However, it is important for the formulation scientists to work closely with patients, carers and clinicians to develop such formulations for both the paediatric and geriatric population.
By way of followup from our recent available presentations on alternative drug delivery approaches, this week’s available download is titled “Improving Adherence with Patient-Centric Formulations” from Ruby Burlage at Merck & Co. This presentation addresses the issue of medication non-adherence and multidimensional factors impacting patient adherence. It also discusses pharmaceutical product design based on target patient profile, the impact of non-adherence on treatment outcomes in diabetes, understanding dosing patterns coupled with patient engagement and the opportunity for patient-centered product design for delivery of biologics.
Our goal is to help you improve the performance of your drug products. The next generation of peptide drug and therapeutic delivery is here. Are you looking to improve the performance of your peptide drug products?
Hear from over 30 peptide drug commercialization experts and connect with 100’s of senior drug product development experts from pharma, biotech and speciality drug development organizations. 2021’s Summit will examine various peptide discovery and synthesis techniques and synthesized and modified peptides. Learn novel strategies for improving peptide stability and half-life, along with novel routes of administration, and walk away with over 2 years of new peptide commercialization strategies in just 2 days!
Register to attend today and walk away with game-changing development strategies which could decrease time-to-market and save you millions. Don’t miss your chance to attend 2021’s one-of-a-kind Summit at the lowest available registration rate!
Join over 1550 senior drug product development professionals in our free Novel Drug Discovery & Development Group. Members of this rapidly growing group will benefit by gaining access to an exclusive network of industry and academic professionals within the drug development arena. Members specialize in discovery, development, formulation, delivery and commercialization of innovative drug products.